SAN DIEGO, May 12, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March 31, 2016. “We have made significant progress in 2016, effectively executing on our clinical development and business […]
DUBLIN, Ireland, May 12, 2016 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced its financial results for the three and nine-month periods ended March 31, 2016. Recent company highlights include: Advanced clinical development and regulatory preparations for ranevetmab (NV-01), for the control of pain associated with osteoarthritis in dogs […]
Northridge, CA, Perth, Australia and Cambridge, UK, 9 May 2016. Link here.
Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom, 3 May 2016 – Link here.
DUBLIN, Ireland, May 02, 2016 (GLOBE NEWSWIRE) – Link here – Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, announced today their research and development collaboration has yielded fully caninized, or ‘100% dog’, monoclonal antibodies (mAbs) that bind and potently inhibit the immuno-oncology […]
29 April, 2016. Link here.
NZX / MEDIA RELEASE 26 April 2016. Link here. Omega-3 update; Omega-2 sales slow; Revised financial guidance SeaDragon Limited (NZX:SEA) is pleased to update the market on the following recent events. Omega-3 Refinery As previously noted to the market, the commissioning of SeaDragon’s new Omega-3 refinery has been successfully completed, with the plant meeting performance […]
April 22, 2016. Link here.
Aesthetics data presented at Skin Regeneration Symposium in Cambridge, UK. 21 April 2016. Link here.
Melbourne, Australia, 21 April 2016. Link here.